| 1.14 -0.07 (-5.79%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.59 | 1-year : | 1.81 |
| Resists | First : | 1.36 | Second : | 1.54 |
| Pivot price | 1.25 |
|||
| Supports | First : | 1.07 | Second : | 0.89 |
| MAs | MA(5) : | 1.15 | MA(20) : | 1.28 |
| MA(100) : | 1.42 |
MA(250) : | 1.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23 |
D(3) : | 20.8  |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 2.73 | Low : | 1.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PACB ] has closed above bottom band by 27.5%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.21 | 1.21 - 1.22 |
| Low: | 1.11 - 1.12 | 1.12 - 1.12 |
| Close: | 1.13 - 1.14 | 1.14 - 1.15 |
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Tue, 18 Aug 2026
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock - Investing.com
Tue, 18 Aug 2026
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock - MarketBeat
Tue, 18 Aug 2026
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding - stocktitan.net
Mon, 17 Aug 2026
Pacific Biosciences of California Inc (PACB) (Q2 2026) Earnings - GuruFocus
Mon, 17 Aug 2026
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing (Aug 17, 2026) - stocktitan.net
Sun, 16 Aug 2026
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 311 (M) |
| Shares Float | 304 (M) |
| Held by Insiders | 8.7 (%) |
| Held by Institutions | 55.5 (%) |
| Shares Short | 46,240 (K) |
| Shares Short P.Month | 60,560 (K) |
| EPS | -0.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -82.5 % |
| Operating Margin | -114.4 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -929.4 % |
| Qtrly Rev. Growth | -1.9 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.72 |
| PEG Ratio | 0 |
| Price to Book value | 114 |
| Price to Sales | 2.22 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|